PMID- 22709877
OWN - NLM
STAT- MEDLINE
DCOM- 20130305
LR  - 20161125
IS  - 0172-6390 (Print)
IS  - 0172-6390 (Linking)
VI  - 59
IP  - 120
DP  - 2012 Nov-Dec
TI  - A new development of FG-CC' siRNA blocking interaction of Tim-1 and Tim-4 can 
      enhance DC vaccine against gastric cancer .
PG  - 2677-82
AB  - BACKGROUND/AIMS: Dendritic cells (DCs) are professional antigen-presenting cells 
      responsible for initiating of immune response. However, because of immune 
      tolerance, it is difficult to induce long-term tumor-specific immune response in 
      humans. This is probably because DCs, which combine with Th2 in the Tim-1/Tim-4 
      pathway, will induce Th2 to proliferation. METHODOLOGY: We have transfected siRNA 
      of FG-CC' gene into DCs stimulated by gastric cancer lysate (lysate-FG-CC-siRNA 
      group), FG-CC-siRNA will block FG-CC' loop,which plays an important role in 
      interaction between Tim-1 and Tim-4. Their potential effect on gastric cancer 
      immunotherapy is assessed by an experimental model. RESULTS: It was observed that 
      lysate-FG-CC-siRNA had the strongest ability of adjusting balance on the Thl/Th2, 
      as a result, these DCs can inhibit gastric cancer growth. In order to test the 
      ability of FG-CC-siR-NA DCs to inhibit tumor growth, we immunized mice 
      subcutaneously with DCs transfected with FG-CC-siR-NA plus tumor antigen. 
      Compared with the control group, a significant inhibition of tumor growth was 
      obvious for the group of lysate-FG-CC-siRNA DC. CONCLUSIONS: We have shown that 
      FG-CC-siRNA blocks FG-CC'loop and significantly enhances the anti-tumor immunity 
      in vitro and in vivo.
FAU - Sun, Hua-Wen
AU  - Sun HW
AD  - Department of Gastrointestinal Surgery, Renmin Hospital of Wuhan University, 
      Wuhan, Hubei Province, China. sunhuawenmail@gmail.com
FAU - Wu, Chong
AU  - Wu C
FAU - Tan, Hai-Yan
AU  - Tan HY
FAU - Wang, Qiu-Shuang
AU  - Wang QS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Hepatogastroenterology
JT  - Hepato-gastroenterology
JID - 8007849
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
RN  - 0 (HAVCR1 protein, human)
RN  - 0 (Hepatitis A Virus Cellular Receptor 1)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Receptors, Virus)
RN  - 0 (TIMD4 protein, human)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal, Murine-Derived/genetics/*metabolism
MH  - *Cancer Vaccines
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cytokines/metabolism
MH  - Dendritic Cells/immunology/*transplantation
MH  - Electroporation
MH  - Female
MH  - Genetic Therapy/*methods
MH  - Hepatitis A Virus Cellular Receptor 1
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating/immunology
MH  - Membrane Glycoproteins/genetics/*metabolism
MH  - Membrane Proteins/genetics/*metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Phenotype
MH  - Protein Binding
MH  - *RNA Interference
MH  - RNA, Small Interfering/*metabolism
MH  - Receptors, Virus/genetics/*metabolism
MH  - Stomach Neoplasms/genetics/immunology/pathology/*therapy
MH  - Th1 Cells/immunology
MH  - Th2 Cells/immunology
MH  - Time Factors
MH  - Transfection
MH  - Tumor Burden
MH  - Xenograft Model Antitumor Assays
EDAT- 2012/06/20 06:00
MHDA- 2013/03/06 06:00
CRDT- 2012/06/20 06:00
PHST- 2012/06/20 06:00 [entrez]
PHST- 2012/06/20 06:00 [pubmed]
PHST- 2013/03/06 06:00 [medline]
AID - 10.5754/hge11620 [doi]
PST - ppublish
SO  - Hepatogastroenterology. 2012 Nov-Dec;59(120):2677-82. doi: 10.5754/hge11620.